IL100553A - ) - (-]] 4-) 1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridecinyl (phenyl [hydrazono] propyl dinitrile - Google Patents

) - (-]] 4-) 1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridecinyl (phenyl [hydrazono] propyl dinitrile

Info

Publication number
IL100553A
IL100553A IL10055391A IL10055391A IL100553A IL 100553 A IL100553 A IL 100553A IL 10055391 A IL10055391 A IL 10055391A IL 10055391 A IL10055391 A IL 10055391A IL 100553 A IL100553 A IL 100553A
Authority
IL
Israel
Prior art keywords
phenyl
methyl
oxo
pyridazinyl
hydrazono
Prior art date
Application number
IL10055391A
Other languages
English (en)
Hebrew (he)
Other versions
IL100553A0 (en
Original Assignee
Orion Yhtymae Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919100049A external-priority patent/GB9100049D0/en
Priority claimed from GB919118947A external-priority patent/GB9118947D0/en
Application filed by Orion Yhtymae Oy filed Critical Orion Yhtymae Oy
Priority to IL11402891A priority Critical patent/IL114028A/en
Publication of IL100553A0 publication Critical patent/IL100553A0/xx
Publication of IL100553A publication Critical patent/IL100553A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Detergent Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Cephalosporin Compounds (AREA)
IL10055391A 1991-01-03 1991-12-30 ) - (-]] 4-) 1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridecinyl (phenyl [hydrazono] propyl dinitrile IL100553A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IL11402891A IL114028A (en) 1991-01-03 1991-12-30 Process for Optical Separation of W (-6-) -4-Aminophenyl (-5-Methyl Pyridazine-H) 23 (Ion and Their Intermediates

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919100049A GB9100049D0 (en) 1991-01-03 1991-01-03 (-)-6-(4-(dicyanomethylidenehydrazino)phenyl)-4,5-dihydro-5-methylpyridazin-3(2h)one
GB919118947A GB9118947D0 (en) 1991-09-05 1991-09-05 Method for the optical resolution of racemic 6-(4-amino-phenyl)-methyl-pyridazin-3(2h)one and preparation of optically active derivatives thereof

Publications (2)

Publication Number Publication Date
IL100553A0 IL100553A0 (en) 1992-09-06
IL100553A true IL100553A (en) 1995-12-31

Family

ID=26298204

Family Applications (2)

Application Number Title Priority Date Filing Date
IL10055391A IL100553A (en) 1991-01-03 1991-12-30 ) - (-]] 4-) 1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridecinyl (phenyl [hydrazono] propyl dinitrile
IL11402891A IL114028A (en) 1991-01-03 1991-12-30 Process for Optical Separation of W (-6-) -4-Aminophenyl (-5-Methyl Pyridazine-H) 23 (Ion and Their Intermediates

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL11402891A IL114028A (en) 1991-01-03 1991-12-30 Process for Optical Separation of W (-6-) -4-Aminophenyl (-5-Methyl Pyridazine-H) 23 (Ion and Their Intermediates

Country Status (32)

Country Link
US (3) US5424428A (de)
EP (1) EP0565546B1 (de)
JP (2) JP2635445B2 (de)
KR (1) KR100207145B1 (de)
AT (1) ATE119525T1 (de)
AU (1) AU645399B2 (de)
BG (1) BG62002B1 (de)
BR (1) BR1100737A (de)
CA (2) CA2314115C (de)
CY (1) CY1878A (de)
DE (1) DE69201640T2 (de)
DK (1) DK0565546T3 (de)
EE (1) EE02946B1 (de)
ES (1) ES2070627T3 (de)
FI (1) FI105183B (de)
GB (1) GB2251615B (de)
GE (1) GEP19991868B (de)
HK (1) HK117395A (de)
HR (1) HRP921251B1 (de)
HU (1) HU218659B (de)
IE (1) IE72101B1 (de)
IL (2) IL100553A (de)
LU (1) LU90920I2 (de)
LV (1) LV11174B (de)
NO (2) NO300682B1 (de)
NZ (1) NZ241194A (de)
PL (2) PL169435B1 (de)
RO (1) RO111847B1 (de)
RU (1) RU2118317C1 (de)
SI (1) SI9112003A (de)
WO (1) WO1992012135A1 (de)
YU (1) YU48767B (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2251615B (en) * 1991-01-03 1995-02-08 Orion Yhtymae Oy (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]pro panedinitrile
GB2266841A (en) * 1992-05-06 1993-11-17 Orion Yhtymae Oy Compounds for use as anti-ischemic medicaments
JP2806192B2 (ja) * 1992-11-02 1998-09-30 日本曹達株式会社 血小板凝集抑制剤
US5856480A (en) * 1994-11-11 1999-01-05 Nippon Soda Co., Ltd. Optically active compound
GB9606474D0 (en) * 1996-03-27 1996-06-05 Orion Yhytmo Oy Method for obtaining pure enantiomers of a pyridazinone derivative
GB9614098D0 (en) * 1996-07-05 1996-09-04 Orion Yhtymae Oy Transdermal delivery of levosimendan
FI973804A (fi) 1997-09-26 1999-03-27 Orion Yhtymae Oy Levosimendaanin oraalisia koostumuksia
FI974578A (fi) * 1997-12-19 1999-06-20 Orion Yhtymae Oyj Menetelmä levosimendaanin antamiseksi
FI980902A (fi) * 1998-04-23 1999-10-24 Orion Yhtymae Oyj Levosimendaanin stabiileja koostumuksia
FI980901A (fi) * 1998-04-23 1999-10-24 Orion Yhtymae Oyj Levosimendaania säädellysti vapauttavia oraalisia koostumuksia
FI104718B (fi) * 1998-06-18 2000-03-31 Orion Yhtymae Oyj [[4-(2-atsido-3-metyyli-5-oksotetrahydrofuran-2-yyli)fenyyli]hydratsono]propaanidinitriili käytettäväksi referenssiaineena levosimendaanierien analyysissä
US5905078A (en) * 1998-06-19 1999-05-18 Orion Corporation Use of a pyridazinone derivative
FI981473A (fi) * 1998-06-25 1999-12-26 Orion Yhtymae Oyj Menetelmä pulmonaalihypertension hoitamiseksi
GB9915179D0 (en) * 1999-06-29 1999-09-01 Orion Corp A method for the treatment or prevention of coronary graft vasospasm
FI109659B (fi) * 1999-09-10 2002-09-30 Orion Yhtymae Oyj Levosimendaanin farmaseuttisia liuoksia
JP2003512328A (ja) * 1999-10-22 2003-04-02 オリオン コーポレーション レボシメンダンの新規用途
FI20001542A (fi) 2000-06-29 2001-12-30 Orion Yhtymae Oyj Menetelmä septisen sokin hoitamiseksi
FI20002525A (fi) * 2000-11-17 2002-05-18 Orion Yhtymae Oyj Tulehduksenvastaisia aineita
FI20002526A (fi) * 2000-11-17 2002-05-18 Orion Yhtymae Oyj Pyridatsinonijohdannaisten uusi käyttö
FI20002755A0 (fi) * 2000-12-15 2000-12-15 Orion Yhtymae Oyj Menetelmä erektiilin dysfunktion hoitamiseen
FI20010233A0 (fi) 2001-02-08 2001-02-08 Orion Corp Menetelmä sydämen vajaatoiminnan hoitoon
FI20011464A0 (fi) 2001-07-04 2001-07-04 Orion Corp Yhdistelmäterapia sydämen vajaatoiminnan hoitoon
FI20030015A0 (fi) * 2003-01-03 2003-01-03 Orion Corp Menetelmä munuaisten vajaatoiminnan hoitamiseksi
WO2004087641A1 (ja) * 2003-03-31 2004-10-14 Daiichi Pharmaceutical Co., Ltd. ヒドラゾン誘導体
DE102004011512B4 (de) 2004-03-08 2022-01-13 Boehringer Ingelheim Vetmedica Gmbh Pharmazeutische Zubereitung enthaltend Pimobendan
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
EP1579862A1 (de) * 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Verwendung von PDE III Ihibitoren zur Reduktion der Herzgrösse in an Herzversagen leidenden Säugern
FI20040674A0 (fi) 2004-05-12 2004-05-12 Orion Corp Menetelmä tromboembolisten sairauksien estoon
FI20040675A0 (fi) * 2004-05-12 2004-05-12 Orion Corp Menetelmä sydämen hypertrofian hoitoon ja estoon
CA2568393A1 (en) * 2004-05-28 2005-12-15 Abbott Laboratories Methods for treating a mammal before, during and after cardiac arrest
EP1858518A1 (de) 2005-03-14 2007-11-28 Orion Corporation Kombinationsbehandlung zur verbesserung der diurese
EP1951227B1 (de) 2005-11-14 2017-04-12 Boehringer Ingelheim Vetmedica GmbH Verwendung von pimobendan zur behandlung von asymptomatischer (okkulter) herzinsuffizienz
EP1920785A1 (de) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Pimobendan-Cyclodextrin Komplex enthaltendes flüssiges Präparat
EP2117551A1 (de) * 2007-01-17 2009-11-18 Orion Corporation Levosimendan zur verwendung bei der behandlung von chronischer klappenkrankheit
ES2436716T3 (es) 2008-11-25 2014-01-03 Boehringer Ingelheim Vetmedica Gmbh Pimobendan para uso en el tratamiento de la cardiomiopatía hipertrófica en gatos
JP5747030B2 (ja) 2009-07-14 2015-07-08 シプラ・リミテッド レボシメンダンの製造方法及びその方法で用いる中間体
EP2825159B1 (de) 2012-03-15 2022-06-22 Boehringer Ingelheim Vetmedica GmbH Pharmazeutische tablettenformulierung für die veterinärmedizinische branche, herstellungsverfahren und verwendung dafür
EP2970145B1 (de) 2013-03-11 2020-05-06 The Broad Institute, Inc. Verbindungen und zusammensetzungen zur behandlung von krebs
EP3021832B9 (de) 2013-07-19 2023-03-15 Boehringer Ingelheim Vetmedica GmbH Konservierte veretherte cyclodextrinderivate mit flüssiger, wässriger pharmazeutischer zusammensetzung
CN104418810A (zh) * 2013-09-04 2015-03-18 北京博时安泰科技发展有限公司 一种左西孟旦的合成新路线
CN103554032A (zh) * 2013-11-12 2014-02-05 江苏正大清江制药有限公司 高光学纯度(-)-6-(4-氨基苯基)-4,5-二氢-5-甲基-3(2h)-哒嗪酮的制备方法
CN103554033A (zh) * 2013-11-12 2014-02-05 江苏正大清江制药有限公司 一种消旋体(±)- 6-(4-氨基苯基)-4,5-二氢-5-甲基-3(2h)-哒嗪酮的拆分方法
HUE032347T2 (en) 2013-12-04 2017-09-28 Boehringer Ingelheim Vetmedica Gmbh Pimobendan improved pharmaceuticals
CN114699528A (zh) 2015-08-13 2022-07-05 布罗德研究所股份有限公司 用于表达pde3a或slfn12的癌症的组合物和方法
CN105784895B (zh) * 2015-10-30 2018-05-22 成都欣捷高新技术开发有限公司 一种用高效液相色谱仪检测左西孟旦中杂质的方法
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
EP3424908A1 (de) 2017-07-07 2019-01-09 Melody Healthcare Pvt. Ltd. Verfahren zur herstellung von levosimendan
US9962384B1 (en) * 2017-09-07 2018-05-08 Korea Institute Of Science And Technology Levosimendan compound for preventing or treating tau-related diseases
CN111548310B (zh) * 2020-05-12 2021-07-02 成都欣捷高新技术开发股份有限公司 一种左西孟旦钠晶型及其制备方法
CN111718299B (zh) * 2020-07-23 2023-03-10 成都欣捷高新技术开发股份有限公司 一种左西孟旦钠晶型b及其制备方法
US11760730B2 (en) 2021-01-11 2023-09-19 Navinta, Llc Process for the preparation of high purity Levosimendan

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB228004A (en) * 1924-01-24 1925-01-29 Daimler Co Ltd Improvements in locking devices for sliding windows
JPS58113180A (ja) * 1981-12-28 1983-07-05 Mitsui Toatsu Chem Inc ピリダジノン誘導体
JPS6193169A (ja) * 1984-10-12 1986-05-12 Sankyo Co Ltd ピリダジノン誘導体及びその製法
US4946842A (en) * 1985-07-05 1990-08-07 Smith Kline & French Laboratories Limited Novel guanidino pyridazinones as cardiac stimulants
JPH0629254B2 (ja) * 1986-09-08 1994-04-20 帝国臓器製薬株式会社 ピリダジノン誘導体
GB8824458D0 (en) * 1988-10-19 1988-11-23 Orion Yhtymae Oy Substituted pyridazinones
GB8903130D0 (en) * 1989-02-11 1989-03-30 Orion Yhtymae Oy Substituted pyridazinones
GB2251615B (en) * 1991-01-03 1995-02-08 Orion Yhtymae Oy (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]pro panedinitrile

Also Published As

Publication number Publication date
EP0565546B1 (de) 1995-03-08
YU200391A (sh) 1994-05-10
FI932618A (fi) 1993-06-09
GB2251615A (en) 1992-07-15
JP3015748B2 (ja) 2000-03-06
US5424428A (en) 1995-06-13
BG97915A (bg) 1994-04-29
NO932367L (no) 1993-06-28
GB9127145D0 (en) 1992-02-19
HRP921251A2 (en) 1995-08-31
GEP19991868B (en) 1999-12-06
DE69201640T2 (de) 1995-08-10
KR100207145B1 (ko) 1999-07-15
RO111847B1 (ro) 1997-02-28
YU48767B (sh) 1999-12-27
ES2070627T3 (es) 1995-06-01
EP0565546A1 (de) 1993-10-20
LU90920I2 (en) 2002-07-17
RU2118317C1 (ru) 1998-08-27
CA2314115C (en) 2004-03-30
EE02946B1 (et) 1996-12-16
HU9301911D0 (en) 1993-09-28
IL114028A0 (en) 1995-10-31
IL114028A (en) 1996-09-12
DE69201640D1 (de) 1995-04-13
DK0565546T3 (da) 1995-05-22
WO1992012135A1 (en) 1992-07-23
NO300682B1 (no) 1997-07-07
US5569657A (en) 1996-10-29
JPH09183767A (ja) 1997-07-15
IE72101B1 (en) 1997-03-12
CA2099262C (en) 2002-03-12
HUT64754A (en) 1994-02-28
PL169415B1 (pl) 1996-07-31
SI9112003A (sl) 1998-10-31
BG62002B1 (bg) 1998-12-30
LV11174A (lv) 1996-04-20
CA2099262A1 (en) 1992-07-04
KR930703266A (ko) 1993-11-29
AU645399B2 (en) 1994-01-13
IE920002A1 (en) 1992-07-15
NO2001021I1 (no) 2001-12-03
HU218659B (hu) 2000-10-28
BR1100737A (pt) 2000-03-21
ATE119525T1 (de) 1995-03-15
LV11174B (en) 1996-12-20
NZ241194A (en) 1993-06-25
CY1878A (en) 1996-04-05
GB2251615B (en) 1995-02-08
FI105183B (fi) 2000-06-30
NO932367D0 (no) 1993-06-28
HK117395A (en) 1995-07-28
IL100553A0 (en) 1992-09-06
PL169435B1 (pl) 1996-07-31
HRP921251B1 (en) 2000-06-30
US5512571A (en) 1996-04-30
FI932618A0 (fi) 1993-06-09
JPH06504275A (ja) 1994-05-19
AU1153592A (en) 1992-08-17
CA2314115A1 (en) 1992-07-04
JP2635445B2 (ja) 1997-07-30

Similar Documents

Publication Publication Date Title
US5512571A (en) (-) 4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl!-hydra-zono!propanedinitrile
AU732489B2 (en) Oral compositions of levosimendan
EP0894087B1 (de) Verfahren um reine enantiomere eines pyridazinonderivates zu erhalten
US4766123A (en) Methylamidine compounds
JPS6124579A (ja) 置換されたフエノキシアルキルアミノプロパノール
JP3229693B2 (ja) ピペラジン誘導体
WO2021190502A1 (zh) 吡啶并嘧啶酮类化合物
SK48294A3 (en) 2-amino-5-cyano-4-chinolyldihydropyridine-3-carboxylic acid esters, method of their production, medicines containing these matters, method of their production and using of these compounds

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
RH Patent void
KB Patent renewed
EXTP Application for extension order is pending
KB Patent renewed
KB Patent renewed
PEL Intention of commissioner to extend period of protection
EXTN Extension order renewed
EXTN Extension order renewed
EXTN Extension order renewed